Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial

Gautschi, Oliver; Rothschild, Sacha I; Li, Qiyu; Matter-Walstra, Klazien; Zippelius, Alfred; Betticher, Daniel C; Früh, Martin; Stahel, Rolf A; Cathomas, Richard; Rauch, Daniel; Pless, Miklos; Peters, Solange; Froesch, Patrizia; Zander, Thilo; Schneider, Martina; Biaggi, Christine; Mach, Nicolas; Ochsenbein, Adrian F

doi:10.1016/j.cllc.2016.11.007

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Authors		Gautschi, Oliver Rothschild, Sacha I Li, Qiyu Matter-Walstra, Klazien Zippelius, Alfred Betticher, Daniel C Früh, Martin Stahel, Rolf A Cathomas, Richard Rauch, Daniel Pless, Miklos Peters, Solange Froesch, Patrizia Zander, Thilo Schneider, Martina Biaggi, Christine Mach, Nicolas Ochsenbein, Adrian F show all authors [1 - 18]
Published in		Clinical lung cancer. 2017, vol. 18, no. 3, p. 303-309
Abstract		Pemetrexed and bevacizumab as single agents have been approved for maintenance therapy after platinum-based induction in patients with advanced nonsquamous non-small-cell lung cancer. It is currently unknown whether bevacizumab plus pemetrexed is superior to pemetrexed alone.
Keywords		Bevacizumab — Chemotherapy — Lung cancer — Maintenance therapy — Pemetrexed
Identifiers		DOI: 10.1016/j.cllc.2016.11.007 PMID: 27993482
Full text		Article (Accepted version) (598 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de chirurgie
Research groups		Cancer du poumon et mésothéliome pleural malin (944) Groupe Mach Nicolas (oncologie) (654)
Citation (ISO format)		GAUTSCHI, Oliver et al. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. In: Clinical lung cancer, 2017, vol. 18, n° 3, p. 303-309. doi: 10.1016/j.cllc.2016.11.007 https://archive-ouverte.unige.ch/unige:93754